Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : autoimmune disorders

Kaigene Licenses KG006 Autoimmune Drug to Taisho for Japan

Kaigene Licenses KG006 Autoimmune Drug to Taisho for Japan
07/31/2026 | Companies
Kaigene, Inc., a U.S. biotechnology company focused on developing next-generation antibody therapies for autoimmune diseases, has announced an exclusive licensing partnership with Taisho Pharmaceutical Co., Ltd., one of Japan's leading pharmaceutical companies. The agreement grants Taisho exclusive...
antibody therapeutics, autoimmune disease treatment, autoimmune disorders, autoimmune therapy, biologics, biotech licensing, biotechnology, Celltrion, clinical development, drug commercialization, drug licensing agreement, FcRn inhibitor, healthcare news, hFcRn inhibitor, immunology, innovative therapeutics, Japan pharmaceutical market, Japanese pharma, Kaigene, KG006, milestone payments, MRCT, Multi-Regional Clinical Trial, neonatal Fc receptor, next-generation antibodies, pharmaceutical partnership, Phase 3 clinical trial, regulatory approval, royalty agreement, Taisho Pharmaceutical

Shifting the narrative on disability

Shifting the narrative on disability
10/31/2022 | Citizenship
U.S. Bank is committed to increasing inclusivity and creating a workplace where everyone can thrive One in every four adult Americans has a disability. While some disabilities are visible, others, such as learning disabilities, autoimmune disorders, or conditions that interfere with an individual's...
access, Americans, autoimmune disorders, brain disorder, BRG, disability, disability barriers, Disability business resource group, Disability Equality Index, employees, inclusion, inclusivity, infrastructure, learning disabilities, Parkinson's disease, support, workplace


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com